Nasal route: an alternative approach for antiemetic drug delivery

Bibliography

• Follet CV, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs 1997;53:206-34
   PubMed Web of Science ®Google Scholar
• Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-89
   PubMed Web of Science ®Google Scholar
• Harrington RA, Hamilton CW, Brogden RN, Metoclopramide an updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-94
   PubMed Web of Science ®Google Scholar
• Pasricha PJ. Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. Chapter 38. In: Hardman JG, Limbird LE, Gilman AG. editors. Goodman&Gilman's the pharmacological basis of therapeutics. 10th edition. New York; McGraw-Hill 2001. p. 1021-36
   Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002;7:967-75
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3-21
   PubMed Web of Science ®Google Scholar
• Behl CR, Pimplaskar HK, Sileno AP, Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87:187-98
   PubMed Web of Science ®Google Scholar
• Cornaz AL, Buri P. Nasal mucosa as an absorption barrier. Eur J Pharm Biopharm 1994;40:261-70
   Web of Science ®Google Scholar
• Jones N. The Nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001;51:5-19
   PubMed Web of Science ®Google Scholar
• Ozsoy Y. Particulate carriers for nasal administration. In: Kumar MNVR. editor. Handbook of particulate drug delivery. California; (Volume 2) American Scientific Publisher; 2008. p. 143-92
   Google Scholar
• Pires A, Fortuna A, Alver G, Intranasal drug delivery: how, why and what for? J Pharm Sci 2009;12:288-311
   Web of Science ®Google Scholar
• Lansey AB, Martin GP. Nasal drug delivery. Chapter 9. In: Hillery AM, Lloyd AW, Swarbrick J. editors. Drug delivery and targeting for pharmacists and pharmaceutical scientists. New York; Taylor & Francis; 2001. p. 215-43
   Google Scholar
• Verdugo P. Goblet cells secretion and mucogenesis. Annu Rev Physiol 1990;52:157-76
   PubMed Web of Science ®Google Scholar
• Lethem MI. The role of tracheobronchial mucus in drug administration to the airways. Adv Drug Deliv Rev 1993;11:271-98
   Web of Science ®Google Scholar
• Schipper NGM, Verhoef JC, Merkus FWHM. The nasal mucociliary clearance of relevance to nasal drug delivery. Pharm Res 1991;8:807-14
   PubMed Web of Science ®Google Scholar
• Martin E, Schipper NGM, Verhoef JC, Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13-38
   PubMed Web of Science ®Google Scholar
• Ozer Y. Alternative applications for drug delivery: nasal and pulmonary routes. In: Mozafari MR. editor. Nanomaterials and nanosystems for biomedical applications. Dordrecht; Springer; 2007. p. 99-12
   Google Scholar
• Karla PK, Kwatra D, Gaudana R, Nasal drug delivery. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. editors. Modified-release drug delivery technology. 2nd edition. (Volume 2) New York; Informa Healthcare 2008. p. 427-50
   Google Scholar
• Bhise SB, Yadav AV. Bioavailability of intranasal drug delivery. Asian J Pharm 2008;2:201-15
   Google Scholar
• Jadhav KR, Gambhire MN, Shaikh IM, Nasal drug delivery system-factors affecting and applications. Curr Drug Ther 2007;2:27-38
   Google Scholar
• Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev 1998;29:147-55
   PubMed Web of Science ®Google Scholar
• Quraishi MS, Jones NS, Mason JDT. The nasal delivery of drugs. Clin Otolaryngol 1997;22:289-01
   PubMed Web of Science ®Google Scholar
• Hussain A, Hamadi S, Kagashima M, Does increasing the lipophilicity of peptides enhance their nasal absorption? J Pharm Sci 1991;80:1180-1
   PubMed Web of Science ®Google Scholar
• Sanders P, Washington N, Frier M, The deposition of solution-based and suspension-based aerosols from metered dose inhalers in healthy subjects and asthmatic patients. S.T.P. Pharm Sci 1997;7:300-6
   Google Scholar
• Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev 1998;2:39-49
   Google Scholar
• Kublik H, Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77
   PubMed Web of Science ®Google Scholar
• Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993;11:329-47
   Web of Science ®Google Scholar
• Washington N, Washington C, Wilson CG. Physiological pharmaceutics: barriers to drug absorption, 2nd edition, Taylor & Francis, New York; 2001, p. 199-220
   Google Scholar
• Sciarra JJ. Aerosols. Chapter 95. In: Gennaro AR. editor. Remington: the Science and practice of pharmacy. 19th edition. Pennsylvania; Mack Publishing Co 1995. p. 1676-92
   Google Scholar
• Costantino HR, Illum L, Brandt G, Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24
   PubMed Web of Science ®Google Scholar
• Ungell AL, Andreasson A, Lundin K, Effects of enzymatic inhibition and increased paracellular shunting on the transport of vasopressin analogues in the rat. J Pharm Sci 1992;81:640-5
   PubMed Web of Science ®Google Scholar
• Corbo DC, Liu JC, Chien YW. Drug absorption through mucosal membranes. Effect of mucosal route and penetrant hydrophilicity. Pharm Res 1989;6:848-52
   PubMed Web of Science ®Google Scholar
• Ingemann M, Frokjaer S, Hovgaard L, Peptide and protein drug delivery systems for non-parenteral routes of administration. Chapter 10. In: Frokjaer S, Hovgaard L. editors. Pharmaceutical formulation development of peptides and proteins. Philadelphia; Taylor & Francis 2000. p. 189-205
   Google Scholar
• McMartin C, Hutchinson LE, Hyde R, Analysis of structural requirements for the absorbtion of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76:535-40
   PubMed Web of Science ®Google Scholar
• Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001;9:267-79
   PubMed Web of Science ®Google Scholar
• Sambhaji S, Pisal AR, Paradkar KR, Pluronic gels for nasal delivery of Vitamin B12 Part I: preformulation study. Int J Pharm 2004;270:37-45
   PubMedGoogle Scholar
• Ozsoy Y, Tuncel T, Can A, In vivo studies on the nasal preparations of ciprofloxacin hydrochloride. Pharmazie 2000;55:607-9
   PubMed Web of Science ®Google Scholar
• Ugwoke MI, Sam E, Van Den Mooter G, Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 1999;181:125-38
   PubMed Web of Science ®Google Scholar
• Callens C, Pringels E, Remon JP. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm 2003;250:415-22
   PubMed Web of Science ®Google Scholar
• Callens C, Ceulemans J, Ludwig A, Rheological study on mucoadhesivity of some nasal powder formulations. Eur J Pharm Biopharm 2003;55:323-8
   PubMed Web of Science ®Google Scholar
• Illum L, Watts P, Fisher AN, Intranasal delivery of morphine. J Pharmacol Exp Ther 2002;301:391-400
   PubMed Web of Science ®Google Scholar
• Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009;14:3754-79
   PubMed Web of Science ®Google Scholar
• Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003;42:1107-28
   PubMed Web of Science ®Google Scholar
• Behl CR, Pimplaskar HK, Sileno AP, Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev 1998;29:117-33
   PubMed Web of Science ®Google Scholar
• Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137-42
   PubMed Web of Science ®Google Scholar
• Merkus FWHM, Verhoef JC, Marttin E, Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999;36:41-57
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Morita T, Hashida M, Effect of absorption promoters on the nasal absorption of drugs with various molecular weights. Int J Pharm 1993;93:91-9
   Web of Science ®Google Scholar
• Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998;29:185-94
   PubMed Web of Science ®Google Scholar
• Abd El-Hameed MD, Kellaway IW. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems. Eur J Pharm Biopharm 1997;44:53-60
   Web of Science ®Google Scholar
• McDonough J, Dixon H, Ladika M. Nasal delivery of micro- and nano-encapsulated drugs. Chapter 8. In: Kulkarni VS. editor. Handbook of non-invasive drug delivery systems. 2010. Burlington; Elsevier, p. 193-208
   Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-65
   PubMed Web of Science ®Google Scholar
• Fransen N, Bjork E, Nystrom C. Development and characterisation of interactive mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery. Eur J Pharm Biopharm 2007;67:370-6
   PubMed Web of Science ®Google Scholar
• Sweetman SC. Martindale, the complete drug reference. 35th edition. Pharmaceutical Press; London; 2007. p. 1526-602
   Google Scholar
• Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy induced emesis. Drugs 2001;61:1553-62
   PubMed Web of Science ®Google Scholar
• The Merck Index. 13th edition. Merck & Co., Inc; New Jersey: 2001
   Google Scholar
• Bateman DN, Kahn C, Davies DS. The pharmacokinetics of metoclopramide in man with observations in the dog. J Clin Pharm 1980;9:371-7
   Web of Science ®Google Scholar
• Comier M, Chao ST, Grupta SK, Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. J Pharm Sci 1999;88:1030-5
   PubMed Web of Science ®Google Scholar
• Aktar B. Studies on the enhancement of in vitro penetration of metoclopramide hydrochloride with terpenes, Istanbul University, Institute of Health Science, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2009
   Google Scholar
• Zaki NM, Awad GA, Nahaed D, Enhanced bioavailability of metoclopramide HCI by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 2002;32:295-307
   Google Scholar
• Dias RJ, Mali KK, Shinde JV, Formulation and evaluation of thermoreversible mucoadhesive nasal gels of metoclopramide. Latin Am J Pharm 2010;29:354-61
   Web of Science ®Google Scholar
• Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: In vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv 2010;17:19-27
   PubMed Web of Science ®Google Scholar
• Sheth P, Zia H, Needham T. Development of a nasal formulation containing ketorolac tromethamine and metoclopramide hydrochloride. S.T.P. Pharm Sci 2002;12:39-44
   Google Scholar
• Zaki NM, Awad GAS, Mortoda ND, Rapid-onset intranasal delivery of metoclopramide hydrochloride part I. Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm 2006;327:89-96
   PubMed Web of Science ®Google Scholar
• Zaki NM, Mortada ND, Awed GAS, Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 2006;327:97-103
   PubMed Web of Science ®Google Scholar
• Bortoli A, Prada A, Confalonieri M, Efficacy and tolerability of metoclopramide nasal spray in the symptomatic therapy of functional dyspepsia. Curr Ther Res 1994;55:1192-200
   Web of Science ®Google Scholar
• Vivien N, Buri P, Balant L, Nasal absorption of metoclopramide administered to man. Eur J Pharm Biopharm 1994;40:228-31
   Web of Science ®Google Scholar
• Tas C, Kose Ozkan C, Savaser A, Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 2006;64:246-54
   PubMed Web of Science ®Google Scholar
• Tas C, Kose Ozkan C, Savaser A, Nasal absorption of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug Deliv 2009;16:167-75
   PubMed Web of Science ®Google Scholar
• Conte U, Conti B, Giunchedi P, Spray dried polylactide microsphere preparation: Influence of the technological parameters. Drug Dev Ind Pharm 1994;20:235-58
   Web of Science ®Google Scholar
• Gavini E, Rassu G, Sonna V, Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol 2005;57:287-94
   PubMed Web of Science ®Google Scholar
• Gavini E, Rassu G, Muzzarelli C, Spray-dried microspheres based on methylpyrrolidone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm 2008;68:245-52
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Gattani SG. Gellan gum microparticles of metoclopramide hydrochloride for intranasal delivery: Development and evaluation. Chem Pharm Bull (Tokyo) 2009;57:388-92
   PubMed Web of Science ®Google Scholar
• Sharma N, Sharma A, Sharma PK, Mucoadhesive thermoreversible nasal delivery system. J Pharm Res 2010;3:991-7
   Google Scholar
• Markus FWHM, Schipper NGM, Hermens WAJJ, Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release 1993;24:201-76
   Web of Science ®Google Scholar
• Marttin E, Verhof JC, Romejin SG, Effects of nasal absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm Res 1995;12:1151-7
   PubMed Web of Science ®Google Scholar
• Florea BI, Cassara ML, Junginger HE, Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003;87:131-8
   PubMed Web of Science ®Google Scholar
• Gurcan D, Okyar A, Ozbek B, Nasal Administration of ciprofloxacin HCl loaded chitosan microspheres: in vitro and in vivo. Eval Acta Pharm Sci 2010;52:5-18
   Google Scholar
• Illum L, Watts P, Fisher AN, Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue S.T.P. Pharm Sci 2000;10:89-94
   Google Scholar
• Soane RJ, Hinchcliffe M, Davis SS, Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183-91
   PubMed Web of Science ®Google Scholar
• Artursson P, Lindmark T, Davis SS, Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2.). Pharm Res 1994;11:1358-61
   PubMed Web of Science ®Google Scholar
• Schipper NGM, Olsson S, Hoogstraate JA, Chitosans as absorption enhancers for poorly absorbable drugs: 2. Mechanism of absorption enhancement. Pharm Res 1997;14:923-9
   PubMed Web of Science ®Google Scholar
• Lehr CM, Bouwstra JA, Schacht EH, In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992;78:43-8
   Web of Science ®Google Scholar
• Henriksen I, Green KL, Smart JD, Bioadhesion of hydrated chitosans: An in vitro and in vivo study. Int J Pharm 1996;145:231-40
   Web of Science ®Google Scholar
• Park K, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery: method to study bioadhesion. Int J Pharm 1984;198:107-27
   Google Scholar
• Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 1998;31:267-85
   PubMed Web of Science ®Google Scholar
• Scarantino CW, Ornitz RD, Hoffman LG. Radiation induced emesis: Effects of ondansetron. Semin Oncol 1992;19:38-43
   PubMed Web of Science ®Google Scholar
• Eilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-94
   PubMed Web of Science ®Google Scholar
• Roila F, Del Fevero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109
   PubMed Web of Science ®Google Scholar
• Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-310
   PubMed Web of Science ®Google Scholar
• Swain K, Pattnaik S, Sahu SC, Drug in adhesive type transdermal matrix system of ondansetron hydrochloride:optimisation of permeation pattern using response surface methodology. J Drug Target 2010;18:106-14
   PubMed Web of Science ®Google Scholar
• Can AS. Developing ondansetron hydrochlorides topical formulations and to examine their percutaneous absorptions, Istanbul University, Institute of Health Sciences, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2011
   Google Scholar
• Ozdin D. Investigation of transdermal iontophoretic delivery of ondansetron hydrochloride. Istanbul University, Institute of Health Science, Department of Pharmaceutical Technology, Master of Science Thesis. Istanbul: 2011
   Google Scholar
• Krishnaiah YS, Bhaskar P, Satyanarayana V. Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes. Pharm Dev Technol 2009;14:53-64
   Web of Science ®Google Scholar
• Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol 2000;45:432-4
   PubMed Web of Science ®Google Scholar
• Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm 2008;349:101-7
   PubMed Web of Science ®Google Scholar
• Bhalarao AV, Lonkar SL, Deshkar SS, Nasal mucoadhesive in situ gel of ondansetron hydrochloride. Indian J Pharm Sci 2009;71:711-13
   Web of Science ®Google Scholar
• Gungor S, Okyar A, Erturk Toker S, Ondansetron- loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes. Drug Dev Ind Pharm 2010;36:806-13
   PubMed Web of Science ®Google Scholar
• Gungor S, Okyar A, Erturk Toker S, Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies. Pharm Dev Technol 2010;15:258-65
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Guttani SG. Nasal administration of ondansetron using a novel microspheres delivery system. Pharm Dev Technol 2009;14:226-32
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Guttani SG. Nasal administration of ondansetron using a novel microspheres delivery system Part II: ex vivo and vivo studies. Pharm Dev Technol 2010;15:653-71
   PubMed Web of Science ®Google Scholar
• Acarturk F, Celkan A. Comparison of guar gum from different sources for the preparation of prolonged-release or colon-specific dosage forms. Pharm Dev Technol 2009;14:271-7
   PubMed Web of Science ®Google Scholar
• Carmicheal J, Cantwell BM, Edwards CM, A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with antiemetic response. Cancer Chemother Pharmacol 1989;24:45-9
   PubMed Web of Science ®Google Scholar
• Woo JS. Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection. Arch Pharm Res 2006;30:778-84
   Web of Science ®Google Scholar
• Cho HJ, Balakrishnan P, Shim WS, Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethyl-cellulose for intranasal delivery. Int J Pharm 2010;400:59-65
   PubMed Web of Science ®Google Scholar
• Chaturvedula A, Joshi DP, Anderson CR, Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery. Pharm Res 2005;22:1313-19
   PubMed Web of Science ®Google Scholar
• Cazares-Delgadillo J, Ganem-Rondero A, Quintanar-Guerrero D, Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. Eur J Pharm Sci 2010;39:387-93
   PubMed Web of Science ®Google Scholar
• Available from: www.drugdeliverytech-online.com
   Google Scholar
• Mahajan H, Shaikh M, Gattani S, In-situ gelling system based on thiolated gellan gum as new carrier for nasal administration of dimenhydrinate. Int J Pharm Sci Nanotechnol 2009;2:544-50
   Web of Science ®Google Scholar
• Yadav AV, Mote HH. Development of biodegradable starch microspheres for intranasal delivery. Indian J Pharm Sci 2008;70:170-4
   PubMed Web of Science ®Google Scholar
• Hafner A, Filipovic Garcie J. Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm 2007;33:427-36
   PubMed Web of Science ®Google Scholar
• Mcdonough JA, Persyn JT, Nino JA, Microcapsule-gel formulation of promethazine HCI for controlled nasal delivery: a motion sickness medication. J Microencapsul 2007;24:109-16
   PubMed Web of Science ®Google Scholar